Literature DB >> 24449061

The presence of oligoclonal IgG bands in human CSF during the course of neurological diseases.

M Haertle1, U Kallweit, M Weller, M Linnebank.   

Abstract

The analysis of cerebrospinal fluid (CSF) is an important tool for the diagnosis of neurological diseases. However, there is limited knowledge about the representativity of a single oligoclonal band (OCB) analysis for a neurological disease during its clinical course. In this study, we analyzed the presence of OCB in the CSF of patients who underwent lumbar puncture more than once. We retrospectively analyzed anonymized data from serial 17,002 CSF analyses done in the CSF laboratory of the Department of Neurology, University Hospital Zurich. We included cases with documented diagnosis in whom OCB were determined more than once. We included 144 patients. The median time span between the first and second OCB analysis was 274 days (range, 1-3,533 days). The result of the second OCB analysis was identical in 109 cases, and different in 35 (24 %). Twenty-five patients acquired and ten patients lost OCB over time. Three of 24 MS patients did not show OCB at the first CSF analysis, but in the second. In the entire group, newly occurring OCB were often associated with new symptoms or occurred after the acute phase of CNS infectious diseases, supposedly as a consequence of the immune reaction. A loss of OCB was often associated with remissions from diseases, e.g., during effective treatment. In patients with neurological diseases, both initially positive and negative OCB results may change over time, which often parallels the clinical condition. Such variability must be taken into account for the interpretation of OCB results.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24449061     DOI: 10.1007/s00415-013-7234-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  25 in total

1.  Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis.

Authors:  Melanie Greter; Frank L Heppner; Maria P Lemos; Bernhard M Odermatt; Norbert Goebels; Terri Laufer; Randolph J Noelle; Burkhard Becher
Journal:  Nat Med       Date:  2005-02-27       Impact factor: 53.440

Review 2.  Perivascular spaces and the two steps to neuroinflammation.

Authors:  Trevor Owens; Ingo Bechmann; Britta Engelhardt
Journal:  J Neuropathol Exp Neurol       Date:  2008-12       Impact factor: 3.685

Review 3.  Cerebrospinal fluid flow imaging by using phase-contrast MR technique.

Authors:  B Battal; M Kocaoglu; N Bulakbasi; G Husmen; H Tuba Sanal; C Tayfun
Journal:  Br J Radiol       Date:  2011-05-17       Impact factor: 3.039

4.  Pattern and concentration of IgG in cerebrospinal fluid in neurosarcoidosis.

Authors:  T F Scott; A R Seay; J M Goust
Journal:  Neurology       Date:  1989-12       Impact factor: 9.910

5.  Is progressive multifocal leukoencephalopathy associated with intrathecal IgG synthesis?

Authors:  P Mazzarello; M Poloni; M Ceroni; R Scelsi
Journal:  J Neuroimmunol       Date:  1985-12       Impact factor: 3.478

6.  Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients.

Authors:  Felipe von Glehn; Alessandro S Farias; Augusto C Penalva de Oliveira; Alfredo Damasceno; Ana Leda F Longhini; Elaine C Oliveira; Benito P Damasceno; Leonilda M B Santos; Carlos Otávio Brandão
Journal:  Mult Scler       Date:  2011-10-31       Impact factor: 6.312

7.  Interpretation of cerebrospinal fluid protein assays in various neurologic diseases.

Authors:  R H Christenson; P Behlmer; J F Howard; J B Winfield; L M Silverman
Journal:  Clin Chem       Date:  1983-06       Impact factor: 8.327

8.  Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?

Authors:  M Tintoré; A Rovira; J Río; C Tur; R Pelayo; C Nos; N Téllez; H Perkal; M Comabella; J Sastre-Garriga; X Montalban
Journal:  Neurology       Date:  2007-09-19       Impact factor: 9.910

9.  Cerebrospinal fluid immunoglobulin abnormalities in systemic lupus erythematosus.

Authors:  J Ernerudh; T Olsson; F Lindström; T Skogh
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-08       Impact factor: 10.154

10.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

View more
  4 in total

Review 1.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

2.  Multiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka.

Authors:  S M K Gamage; I Wijeweera; S B Adikari; Katharina Fink; Jan Hillert; Anna Fogdell-Hahn; H M A Sominanda
Journal:  Mult Scler Int       Date:  2018-02-28

3.  Cerebrospinal fluid humoral immunity in the differential diagnosis of multiple sclerosis.

Authors:  Evanthia Bernitsas; Omar Khan; Sara Razmjou; Alexandros Tselis; Fen Bao; Christina Caon; Scott Millis; Navid Seraji-Bozorgzad
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

4.  Cerebrospinal fluid findings in neurological diseases associated with COVID-19 and insights into mechanisms of disease development.

Authors:  Otávio Melo Espíndola; Carlos Otávio Brandão; Yago Côrtes Pinheiro Gomes; Marilda Siqueira; Cristiane Nascimento Soares; Marco Antônio Sales Dantas Lima; Ana Claudia Celestino Bezerra Leite; Guilherme Torezani; Abelardo Queiroz Campos Araujo; Marcus Tulius Teixeira Silva
Journal:  Int J Infect Dis       Date:  2020-10-28       Impact factor: 3.623

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.